首页> 美国卫生研究院文献>other >A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed Refractory or Secondary Acute Myeloid Leukemia: A Report from the Childrens Oncology Group

【2h】

A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed Refractory or Secondary Acute Myeloid Leukemia: A Report from the Childrens Oncology Group

机译：硼替佐米联合伊达比星/阿糖胞苷或阿糖胞苷/依托泊苷治疗复发性难治性或继发性急性髓性白血病儿童的第二阶段研究：儿童肿瘤学组的报告

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThis Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiating cells (AML-LIC) before and after treatment.

机译：背景这项2期研究测试了硼替佐米联合还原化疗对小儿复发，难治性或继发性急性髓细胞性白血病（AML）的耐受性和疗效。相关研究测量了治疗前后推定的AML白血病起始细胞（AML-LIC）。

著录项

期刊名称 other
作者
Terzah M. Horton; John P. Perentesis; Alan S. Gamis; Todd A. Alonzo; Robert B. Gerbing; Jennifer Ballard; Kathleen Adlard; Dianna S. Howard; Franklin O. Smith; Gaye Jenkins; Angelé Kelder; Gerrit J. Schuurhuis; Jeffrey A. Moscow;
展开▼
作者单位

展开▼
年(卷),期 -1(61),10
年度 -1
页码 1754–1760
总页数 18
原文格式 PDF
正文语种
中图分类
关键词
AML AraC pediatric oncology relapse Velcade;

机译：AML;AraC;儿科肿瘤学;复发;Velcade;

相似文献

外文文献
中文文献
专利

1. A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group [J] . Horton Terzah M., Perentesis John P., Gamis Alan S., Pediatric blood & cancer . 2014,第10期

机译：硼替佐米联合伊达比星/阿糖胞苷或阿糖胞苷/依托泊苷治疗复发性，难治性或继发性急性髓性白血病儿童的第二阶段研究：儿童肿瘤学组的报告
2. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. [J] . Wells RJ, Adams MT, Alonzo TA, Journal of Clinical Oncology . 2003,第15期

机译：儿童复发或难治性急性髓细胞性白血病的儿童米托蒽醌和阿糖胞苷的诱导，大剂量阿糖胞苷和依托泊苷的强化治疗：儿童癌症小组研究2951。
3. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03) [J] . Cooper Todd M., Sison Edward Allan Racela, Baker Sharyn D., Pediatric blood & cancer . 2017,第8期

机译：CXCR4拮抗剂脊布料中与高剂量的急性白血病或骨髓增生综合征或髓细胞增强综合征的儿童组合的CXCR4拮抗剂柱和依托泊苷的第1相研究：小儿肿瘤学实验治疗研究人员联盟研究（POE 10-03）
4. Clinical Trials for Childhood Acute Myeloid Leukemia at St. Jude Children's Research Hospital, 1980 through 2005 [C] . . 2006

机译：1980年至2005年在圣裘德儿童研究医院进行的儿童急性髓性白血病临床试验
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. A Phase 1 Study of the CXCR4 Antagonist Plerixafor in Combination With High-Dose Cytarabine and Etoposide in Children With Relapsed or Refractory Acute Leukemias or Myelodysplastic Syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium Study (POE 10-03) [O] . Todd M. Cooper, Edward Allan Racela Sison, Sharyn D. Baker, -1

机译：CXCR4拮抗剂Plerixafor与大剂量阿糖胞苷和依托泊苷联合用于复发或难治性急性白血病或骨髓增生异常综合症儿童的1期研究：儿童肿瘤实验治疗研究者联合体研究（POE 10-03）
7. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia [O] . Prajwal Boddu, Gautam Borthakur, Mythili Koneru, 2018

机译：Ly2510924，inArubicin和复发性急性髓鞘骨髓白血病初期初期研究

A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed Refractory or Secondary Acute Myeloid Leukemia: A Report from the Childrens Oncology Group

摘要

著录项

相似文献

相关主题

期刊订阅